Table 1.

Baseline characteristics of patients according to neoadjuvant chemotherapy regimen (n = 450)

	Non-carboplatin (N = 247)	Carboplatin (N = 120)	Pembrolizumab (N = 83)	Total (N = 450)	P
Age, n (%)					0.630
≤ 50	143 (57.9)	75 (62.5)	47 (56.6)	265 (58.9)
> 50	104 (42.1)	45 (37.5)	36 (43.4)	185 (41.4)
Germline BRCA1/2 mutation*					0.090
No	86 (81.9)	64 (70.3)	56 (82.4)	206 (78.0)
Yes	19 (18.1)	27 (29.7)	12 (17.6)	58 (22.0)
Clinical tumor stage					0.156
1	14 (5.7)	7 (5.8)	6 (7.2)	27 (6.0)
2	163 (66.0)	91 (75.8)	62 (74.7)	316 (70.2)
3	51 (20.6)	18 (15.0)	14 (16.9)	83 (18.4)
4	19 (7.7)	4 (3.3)	1 (1.2)	24 (5.3)
Clinical nodal stage					0.280
0	47 (19.0)	25 (20.8)	11 (13.3)	83 (18.4)
1	100 (40.5)	51 (42.5)	43 (51.8)	194 (43.1)
2	87 (35.2)	36 (30.0)	21 (25.3)	144 (32.0)
3	13 (5.3)	8 (6.7)	8 (9.6)	29 (6.4)
Clinical Stage, n (%)					0.133
I, IIA	49 (19.8)	24 (20.0)	13 (15.7)	86 (19.1)
IIB	75 (30.4)	41 (34.2)	37 (44.6)	153 (34.0)
IIIA	93 (37.7)	43 (35.8)	24 (28.9)	160 (35.6)
IIIB	17 (6.9)	4 (3.3)	1 (1.2)	22 (4.9)
IIIC	13 (5.3)	8 (6.7)	8 (9.6)	29 (6.4)
Histologic grade*, n (%)					0.369†
1	4 (2.2)	0	1 (1.3)	5 (1.3)
2	85 (47.0)	53 (46.5)	44 (55.0)	182 (48.5)
3	92 (50.8)	61 (53.5)	35 (43.8)	188 (48.5)
sTILs, median (range)	20 (10–60)	20 (3–40)	10 (3–25)	20 (3–40)	< 0.001
sTILs*, %					0.009
< 50	120 (68.2)	90 (78.9)	67 (84.8)	277 (75.1)
≥ 50	56 (31.8)	24 (21.1)	12 (15.2)	92 (24.9)
Surgery type					0.512
Lumpectomy	137 (55.5)	74 (61.7)	49 (59.0)	260 (57.8)
Mastectomy	110 (44.5)	46 (38.3)	34 (41.0)	190 (42.2)

^*Missing values ^†P-values were obtained with the Fisher’s exact test. sTILs, stromal tumor-infiltrating lymphocytes